Clinical Guidelines

nccn recommendation
Fam-trastuzumab
deruxtecan-nxki (ENHERTU®):
The only preferred anti-HER2 treatment option that is NCCN-recommended for 2L+ HER2+ advanced gastric/GEJ adenocarcinoma (Category 2A)1,2,a

 

Preferred 1L treatment

Preferred 2L anti-HER2 treatment

HER2
overexpressing
advanced
gastric/GEJ
adenocarcinoma

Preferred 1L treatment

Trastuzumab +
fluoropyrimidine (fluorouracil
or capecitabine) +
cisplatin (Category 1) or
oxaliplatin (Category 2A)

Preferred 2L anti-HER2 treatment

Fam-trastuzumab
deruxtecan-nxki (ENHERTU®)
(Category 2A)

aFam-trastuzumab deruxtecan-nxki (ENHERTU®) is recommended (Category 2A) as a preferred 2L or subsequent therapy for HER2 overexpression positive gastric or gastroesophageal adenocarcinoma, where local therapy is not indicated for unresectable locally advanced, recurrent or metastatic disease. The National Comprehensive Cancer Network® (NCCN®) makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. For detailed recommendations, see the NCCN Guidelines® for Gastric Cancer and for Esophageal and Esophagogastric Junction Cancers at NCCN.org.1,2

Ready to learn more about ENHERTU?

1L, first line; 2L, second line; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; NCCN, National Comprehensive Cancer Network.